Recent insights into the biology of bone turnover

Journal of the Royal College of Physicians of Edinburgh

Volumn 40, Issue 1, 2010, Pages 66-69

  Riches, P L ^a   Ralston, S H ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Osteoporosis; Osteoprotegerin; RANK; RANK ligand

Indexed keywords

CALCIUM; DENOSUMAB; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; VITAMIN D; ZOLEDRONIC ACID;

ALBERS SCHOENBERG DISEASE; BONE BIOPSY; BONE MARROW CELL; BONE TURNOVER; COMPETITIVE INHIBITION; CONFERENCE PAPER; DIET SUPPLEMENTATION; GENE MUTATION; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PATHOGENESIS; POSTMENOPAUSE OSTEOPOROSIS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ADULT; ANTIBODIES, MONOCLONAL; BONE AND BONES; HOMEOSTASIS; HUMANS; MALE; MUTATION; OSTEITIS DEFORMANS; OSTEOCLASTS; OSTEOPETROSIS; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPROTEGERIN; RANK LIGAND;

EID: 77949494842     PISSN: 14782715     EISSN: None     Source Type: Journal    
DOI: 10.4997/JRCPE.2010.113     Document Type: Conference Paper

References (39)

1. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 2001; 142:5050-5. doi:10.1210/en.142.12.5050
2. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165-76. doi:10.1016/S0092-8674(00)81569-X
3. Hsu H, Lacey DL, Dunstan CR et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999; 96:3540-5. doi:10.1073/pnas.96.7.3540
4. Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002; 20:795-823. doi:10.1146/annurev.immunol.20.100301.064753
5. Blair JM, Zheng Y, Dunstan CR. RANK ligand. Int J Biochem Cell Biol 2007; 39:1077-81. doi:10.1016/j.biocel.2006.11.008
6. Gori F, Hofbauer LC, Dunstan CR et al. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 2000; 141:4768-76. doi:10.1210/en.141.12.4768
7. Kong YY, Yoshida H, Sarosi I et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397:315-23. doi:10.1038/16852
8. Dougall WC, Glaccum M, Charrier K et al. RANK is essential for osteoclast and lymph node development. Genes Dev 1999; 13:2412-24. doi:10.1101/gad.13.18.2412
9. Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci 2008; 1143:123-50. doi:10.1196/annals.1443.016
10. Villa A, Guerrini M, Cassani B et al. Infantile malignant, autosomal recessive osteopetrosis: the rich and the poor. Calcif Tissue Int 2009; 84:1-12. doi:10.1007/s00223-008-9196-4
11. Bianchi ML, Bardella MT. Bone and celiac disease. Calcif Tissue Int 2002; 71:465-71. doi:10.1007/s00223-001-2131-6
12. Noble CL, McCullough J, Ho W et al. Low body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27:588-96.
13. Van Staa TP, Geusens P, Bijlsma JW et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:3104-12. doi:10.1002/art.22117
14. Goldring SR, Gravallese EM. Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications. Arthritis Res 2000; 2:33-7. doi:10.1186/ar67
15. Kong YY, Feige U, Sarosi I et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402:304-9. doi:10.1038/46303
16. Cohen SB, Dore RK, Lane NE et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arth Rheum 2008; 58:1299-309. doi:10.1002/art.23417
17. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone 2002; 30:340-6. doi:10.1016/S8756-3282(01) 00682-2
18. Taranta A, Fortunati D, Longo M et al. Imbalance of osteoclastogenesis- regulating factors in patients with celiac disease. J Bone Miner Res 2004; 19:1112-21. doi:10.1359/JBMR.040319
19. Hofbauer LC, Gori F, Riggs BL et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999; 140:4382-9. doi:10.1210/en.140.10.4382
20. Bezerra MC, Calomeni GD, Caparbo VF et al. Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. Rheumatology 2005; 44:1503-6. doi:10.1093/rheumatology/kei045
21. Moschen AR, Kaser A, Enrich B et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005; 54:479-87. doi:10.1136/gut.2004.044370
22. Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor κB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005; 90:6323-31. doi:10.1210/jc.2005-0794
23. Findlay D, Chehade M, Tsangari H et al. Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. Arthritis Res Ther 2008; 10:R2. doi:10.1186/ar2348
24. Cooper C, Schafheutle K, Dennison E et al. The epidemiology of Paget's disease in Britain: is the prevalence decreasing? J Bone Miner Res 1999; 14:192-7. doi:10.1359/jbmr.1999.14.2.192
25. Daroszewska A, Ralston SH. Genetics of Paget's disease of bone. Clin Sci (Lond) 2005; 109:257-63. doi:10.1042/CS20050053
26. Hughes AE, Ralston SH, Marken J et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 2000; 24:45-8. doi:10.1038/71667
27. Nakatsuka K, Nishizawa Y, Ralston SH. Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. J Bone Miner Res 2003; 18:1381-5. doi:10.1359/jbmr.2003. 18.8.1381
28. Whyte MP, Hughes AE. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res 2002; 17:26-9. doi:10.1359/jbmr.2002.17.1.26
29. Chong B, Hegde M, Fawkner M et al. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone Miner Res 2003; 18:2095-104. doi:10.1359/jbmr.2003.18.12.2095
30. Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget's disease of bone. Lancet 2008; 372:155-63. doi:10.1016/S0140-6736(08) 61035-1
31. Rivadeneira F, Styrkársdottir U, Estrada K et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet 2009; 41:1199-206. doi:10.1038/ng.446
32. Bord S, Ireland DC, Beavan SR et al. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 2003; 32:136-41. doi:10.1016/S8756-3282(02)00953-5
33. Yano K, Tsuda E, Washida N et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. J Bone Miner Res 1999; 14:518-27. doi:10.1359/jbmr.1999.14.4.518
34. Riches PL, McRorie E, Fraser WD et al. Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. N Engl J Med 2009; 361:1459-65. doi:10.1056/NEJMoa0810925
35. Bekker PJ, Holloway D, Nakanishi A et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 2001; 16:348-60. doi:10.1359/jbmr.2001.16.2.348
36. Cummings SR, Martin JS, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756-65. doi:10.1056/NEJMoa0809493
37. He MM, Smith AS, Oslob JD et al. Small-molecule inhibition of TNF-α. Science 2005; 310:1022-5. doi:10.1126/science.1116304
38. Akiyama T, Shimo Y, Yanai H et al. The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 2008; 29:423-37. doi:10.1016/j.immuni.2008.06.015
39. Hanada R, Leibbrandt A, Hanada T et al. Central control of fever and female body temperature by RANKL/RANK. Nature 2009; 462:505-9. doi:10.1038/nature08596